IL6 and systemic sclerosis: Nintedanib, a tyrosine kinase inhibitor, was recently approved as the first targeted therapy for SSc-associated interstitial lung disease (ILD).5 Additio-nal emerging treatments include anti-interleukin (IL)-6, anti-transforming growth factor (TGF)-β, anti-cytotoxic T-lymphocyte associated (CTLA) protein 4, and Janus-kinase inhibitors (JAKi).5 We report a case of a patient with diffuse, multisystem SSc who responded well to upadacitinib, a JAKi.